IQVIA Expands Kexing Biopharm Partnership to Accelerate Global Biosimilar Development with AI
Event summary
- IQVIA and Kexing Biopharm have expanded their strategic collaboration to support a global, multi-product biosimilar development and commercialization program.
- The partnership leverages IQVIA’s end-to-end capabilities across clinical development, regulatory strategy, advanced analytics, and commercialization.
- AI-enabled clinical trial capabilities will enhance speed, efficiency, and decision-making throughout the development process.
- Kexing Biopharm aims to accelerate its internationalization strategy with IQVIA’s global execution capabilities and AI-powered solutions.
The big picture
This collaboration underscores the growing trend of AI integration in clinical trials to enhance efficiency and decision-making. It also highlights the strategic importance of biosimilars in expanding global market reach, particularly for biopharmaceutical companies aiming to reduce development timelines and costs. The partnership reflects IQVIA’s broader strategy to leverage its global data resources and AI capabilities to support biopharmaceutical companies in navigating complex regulatory environments.
What we're watching
- AI Integration
- How effectively IQVIA’s AI-powered solutions streamline biosimilar development and improve trial performance.
- Regulatory Efficiency
- Whether the collaboration can mitigate regulatory risks and improve overseas registration efficiency for Kexing Biopharm.
- Global Expansion
- The pace at which Kexing Biopharm can scale its biosimilar portfolio in international markets with IQVIA’s support.
Related topics